Aug 27, 2026, 8:37 AMAnalyst Ratings
Novo Nordisk Cut to Sell by Deutsche Bank After 70% Stock Collapse
Deutsche Bank cut Novo Nordisk to sell on Aug. 27, 2026, after the Ozempic maker's shares plunged 70% from their peak, according to MarketWatch, in a rare move.
Listen to this briefingAudio briefing
Summary
Deutsche Bank downgraded Novo Nordisk, the maker of Ozempic, to sell on Thursday, August 27, 2026, after its stock price fell 70% from its peak. The call broke with Wall Street analysts' previous reluctance to recommend selling the shares despite the company's tough period.
Only a short MarketWatch feed summary was available. It provided no analyst name, price target, valuation, downgrade rationale, financial data, or expected next steps beyond Deutsche Bank's rating change.
Positives
- Wall Street analysts had remained reluctant to recommend selling Novo Nordisk despite the company's difficulties.
- Deutsche Bank was the only brokerage identified as breaking from that prior reluctance on August 27, 2026.
- The available feed disclosed no new earnings shortfall, regulatory setback, or operational deterioration accompanying the downgrade.
Risks & concerns
- Novo Nordisk's stock price had fallen 70% from its peak before Deutsche Bank issued its sell rating.
- Deutsche Bank's downgrade ended Wall Street's previous reluctance to advise investors to sell the shares.
- MarketWatch described Novo Nordisk as facing tough times, although the available summary did not specify the underlying problems.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/ozempic-maker-novo-nordisk-downgraded-to-sell-after-70-stock-price-dive-from-peak-90193914?mod=mw_rss_topstories
Read full article
